MDGL
Madrigal Pharmaceuticals Inc
$72.84
Earnings Summary
Net Profits | $-70.73Mn |
Highlights
Madrigal Pharmaceuticals Inc’s net profit fell -14.73% since last year same period to $-70.73Mn in the Q2 2022. On a quarterly growth basis, Madrigal Pharmaceuticals Inc has generated -22.97% fall in its net profits since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Madrigal Pharmaceuticals Inc post its latest quarter earnings
EPS Estimate Current Quarter | -3.7 |
EPS Estimate Current Year | -3.7 |
Highlights
Madrigal Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -3.7 - a -2.21% fall from last quarter’s estimates.
Madrigal Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -3.7.
Key Ratios
Key ratios of the Madrigal Pharmaceuticals Inc post its Q2 2022 earnings
Return on Assets (ROA) | -0.59 |
Return on Equity (ROE) | -1.45 |
Dividend Per Share (DPS) | 0 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Madrigal Pharmaceuticals Inc’s return on assets (ROA) stands at -0.59.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Madrigal Pharmaceuticals Inc’s return on equity (ROE) stands at -1.45.
Madrigal Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q2 2022.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2022-05-09 | -3.62 | -3.36 | 7.18% |
Company Information
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. Madrigal recognizes that compounds with greater selectivity for thyroid hormone receptor (THR)-ß and liver uptake has the greatest potential to overcome challenges faced by prior, less selective compounds and deliver the full therapeutic potential of THR-ß agonism. The Company believes that resmetirom, its lead product candidate, is the first orally administered, small-molecule, liver-directed, truly ß-selective THR agonist.
Organisation | Madrigal Pharmaceuticals Inc |
Headquarters | Fort Washington, Pennsylvania, US |
Employees | 42 |
Industry | Health Technology |
CEO | Rebecca Taub |